Merck Shuts Down London Drug Discovery Centre, Moves R&D Focus to US
Merck has announced that it will discontinue its drug discovery operations in London, citing an increasingly challenging business environment in the UK. The company has abandoned plans to occupy the Belgrove House site at King’s Cross—which had been scheduled to open in 2027—and will relocate research activities primarily to existing sites in the USA.
Francis Crick Institute | 12/09/2025 | By Darshana
Apriori Bio Partners with Francis Crick Institute to Advance Variant-Resilient Vaccine Research
Apriori Bio has partnered with the Francis Crick Institute to leverage AI-driven insights and the Crick’s Legacy Study for developing variant-resilient vaccines against current and emerging viral threats.
Francis Crick Institute | 14/08/2025 | By Mrinmoy Dey
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy